Adimab has initiated two independent collaborations with Biogen Idec and Novo Nordisk.

Adimab and Biogen Idec of Weston, MA, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Biogen Idec. The agreement gives Biogen Idec the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.

Adimab and Novo Nordisk, of Denmark, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Novo Nordisk. The agreement gives Novo Nordisk the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.